SIM0708 / Simcere - LARVOL DELTA

SIM0708 an antibody-drug conjugate (ADC) with half-life extended anti-IL-4 receptor a (IL-4Ra) antibody and glucocorticoid receptor modulator exhibits superior efficacy treating inflammatory diseases (IMMUNOLOGY 2025) - "Enhanced therapeutic window was also observed comparing to oral prednisolone, and no obvious systemic glucocorticoid-related safety risks existed. In addition, favorable developability supports subcutaneous formulation of this ADC. Conclusion : These results suggest that SIM0708 may provide the rapid and improved efficacy beyond anti-IL-4R a antibody alone in inflammatory diseases while minimizing the systemic side effects."

Clinical • Asthma • Atopic Dermatitis • Chronic Obstructive Pulmonary Disease • Dermatitis • Dermatology • Immunology • Inflammation • Respiratory Diseases • IL4 • IL4R

Preclinical data of four innovative autoimmune drugs from Innovent will be published in 2025AAI [Google translation] (Simcere Press Release) - "Interleukin-4 receptor alpha (IL-4Rα) is a key therapeutic target for autoimmune diseases such as atopic dermatitis....SIM0708 is a new antibody-drug conjugate (ADC) developed by Innovent Biologics, which couples the IL-4Rα antibody with a proprietary glucocorticoid payload and introduces a half-life extension design. The molecule showed potent glucocorticoid receptor activation and B cell activation inhibition in preclinical studies, and it took effect quickly in the mouse dermatitis model and had better efficacy than anti-IL-4Rα antibodies. Compared with oral prednisolone, SIM0708 has a larger therapeutic window and good safety, and is expected to be developed into a new anti-autoimmune disease drug that is safer and more effective than existing therapies."

Preclinical • Atopic Dermatitis